Praxis Precision Medicines, Inc. Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Praxis Precision Medicines (PRAX) was upgraded by Wolfe Research to "strong-buy".
A Look At Praxis Precision Medicines (PRAX) Valuation After Recent Share Price Momentum [Yahoo! Finance]
Praxis Precision Medicines (NASDAQ:PRAX) is now covered by analysts at Wolfe Research. They set an "outperform" rating on the stock.
Praxis Precision Medicines (NASDAQ:PRAX) had its price target raised by analysts at Truist Financial Corporation from $500.00 to $700.00. They now have a "buy" rating on the stock.